Jefferies Financial Group Inc. Makes New $6.79 Million Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Jefferies Financial Group Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 350,029 shares of the company’s stock, valued at approximately $6,787,000. Jefferies Financial Group Inc. owned 1.00% of Oruka Therapeutics at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $54,000. AlphaCentric Advisors LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $144,000. Wellington Management Group LLP increased its stake in shares of Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock valued at $1,844,000 after buying an additional 12,952 shares during the period. Finally, Geode Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the third quarter valued at approximately $343,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Down 2.2%

Shares of ORKA stock opened at $9.54 on Monday. The stock has a market cap of $357.19 million, a price-to-earnings ratio of -1.52 and a beta of 0.25. The business’s fifty day moving average is $9.95 and its 200 day moving average is $15.36. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.19. Equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Venrock Healthcare Capital Par bought 88,794 shares of the company’s stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the acquisition, the insider now owns 4,148,428 shares of the company’s stock, valued at $47,458,016.32. The trade was a 2.19% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 22.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ORKA. Wedbush reissued an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Friday, March 7th. Wolfe Research began coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.